BioNTech's COVID-19 Booster Trial Halted Amid Recruitment Challenges

BioNTech halts a US COVID-19 vaccine trial due to low enrollment but remains financially robust with €17.2B cash. The firm shifts focus to oncology as analysts cut 2026 EPS forecasts.

BioNTech and its partner Pfizer have discontinued a U.S. clinical trial for a COVID-19 booster vaccine targeting adults aged 50 to 64. The study's termination was driven by an inability to enroll sufficient participants. More than 80% of potential candidates either failed the pre-screening process or declined to take part, rendering the target recruitment of 25,000 to 30,000 individuals unattainable.

Financial Resilience Amid Setback

Despite this clinical setback, BioNTech's financial position remains robust. The company concluded its 2025 fiscal year with revenues of €2.87 billion, marking a 4.3% increase. It holds cash reserves of approximately €17.2 billion and generated a positive operating cash flow of €403 million. This financial strength provides a stark contrast to competitor Moderna, which reported a 39.2% decline in revenue and a net loss of $2.8 billion for 2025.

The trial's cancellation comes at a challenging juncture. In May 2025, the U.S. Food and Drug Administration (FDA) introduced new requirements mandating placebo-controlled study data specifically for this age cohort, complicating an already difficult recruitment landscape.

Analyst Outlook and Strategic Pivot to Oncology

Concurrently, the analysis firm HC Wainwright has significantly revised its earnings per share (EPS) forecast for BioNTech for the full year 2026 down to -$4.57. This adjustment comes even as the firm maintains a $130 price target and a Buy rating on the stock. For the first and second quarters of 2026, HC Wainwright anticipates losses per share of -$2.41 and -$2.43, respectively.

The company's strategic focus is firmly shifting toward oncology, a transition supported by its solid balance sheet. BioNTech aims to have 15 oncology programs in Phase 3 trials by the end of 2026. A key near-term milestone is the planned regulatory submission for Trastuzumab Pamirtecan in HER2-positive endometrial cancer this year.

To bolster this strategic direction, BioNTech's supervisory board is set to expand from six to eight members at the Annual General Meeting on May 15, 2026, aiming to incorporate additional oncology expertise. Furthermore, the company plans to spin off its next-generation mRNA research into a separate entity by the end of the first half of 2026. This move is designed to allow the core business to concentrate entirely on its cancer pipeline.